세포독성 의약품 및 HPAPI 제조 시장 : 업계 동향과 세계 예측(-2035년) - 제품 유형별, 기업 규모별, 사업 규모별, 분자 유형별, 고활성 최종제형 유형별, 주요 지역별

Cytotoxic Drugs and HPAPI Manufacturing Market: Overview

As per Roots Analysis, the global cytotoxic drugs and HPAPI manufacturing market is estimated to grow from USD 13.98 billion in the current year to USD 46.41 billion by 2035, at a CAGR of 12.75% during the forecast period, till 2035.

The market opportunity for cytotoxic drugs and HPAPI manufacturing market has been distributed across the following segments:

Type of Product

• HPAPIs
• Highly Potent Finished Dosage Forms

Scale of Operation

• Preclinical
• Clinical
• Commercial

Type of Molecule

• Small Molecules
• Biologics

Type of Highly Potent Finished Dosage Form

• Injectables
• Oral Solids
• Creams
• Others

Key Geographies

• North America (US, Canada and Mexico)
• Europe (UK, Italy, Germany, France, Spain, and Rest of Europe)
• Asia-Pacific (China, India, and Rest of Asia-Pacific)
• Rest of the World

Cytotoxic Drugs and HPAPI Manufacturing Market: Growth and Trends

Due to the progress in clinical pharmacology and oncology, along with rising interest of players in targeted therapies, researchers and drug manufacturers worldwide are increasingly focusing on high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs. It is important to note that 45% of drugs worldwide are highly potent, necessitating the need for specialized production of HPAPIs. However, the manufacturing of HPAPIs involves a complicated process, leading to various challenges. The primary challenge is preventing cross-contamination during production, followed by ensuring the safety of the environment and workers involved in the supply chain. Additionally, selecting the appropriate containment and protective measures, including equipment, procedures, and personal protective equipment (PPE), is crucial. Handling HPAPIs typically requires ongoing investment in safe handling practices, and advanced technical expertise, which further complicates the field. As a result, drug developers are increasingly turning to outsourcing their manufacturing processes.

Owing to the significant potential and favorable growth prospects of the contract manufacturing sector, most of the leading pharmaceutical companies are seeking to invest in the expansion or enhancement of their existing manufacturing facilities. Several contract manufacturing organizations (CMOs) are establishing new facilities in emerging markets such as Japan, China, India, and Brazil to benefit from lower production costs, skilled labor, and favorable regulatory environments in these regions. Driven by the overall expansion of the market, recent technological innovations, and a rising trend towards outsourcing, the sector is expected to experience consistent growth in the next decade.

Cytotoxic Drugs and HPAPI Manufacturing Market: Key Insights

The report delves into the current state of the cytotoxic drugs & HPAPI manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

• Presently, more than 140 players claim to have the required expertise to offer contract manufacturing services for highly potent compounds, across different scales of operation.
• The current market landscape is highly fragmented, featuring the presence of both new entrants and established players across key geographical regions.

• Leveraging their expertise, stakeholders are offering contract manufacturing services for a myriad of highly potent compounds; around 70% of the service providers possess analytical testing capability for HPAPIs.
• The growing interest in this domain is evident from the rise in partnership activity; in fact, the maximum number of collaborations related to HPAPI and cytotoxic drug manufacturing were inked in the recent past.
• In order to meet the rising demand for high potency compounds, CMOs have made elaborate investments to expand their facilities and capacities; this trend is most pronounced in the US, Switzerland and the UK.
• The installed global contract manufacturing capacity for HPAPIs is well distributed across different geographies; 80% of the present capacity is installed in facilities owned by very large players.
• Antibody Drug Conjugates are one of the most popular classes of highly potent compounds; more than 30 players currently claim to offer contract manufacturing / conjugation services for such biopharmaceuticals.
• It is anticipated that the highly potent drug developers are likely to outsource their manufacturing operations, enabling the service based revenues to grow at an annualized rate of 12.75%.

Cytotoxic Drugs & HPAPI Manufacturing Market: Key Segments

HPAPI Segment Occupies the Largest Share of the Cytotoxic Drugs and HPAPI Manufacturing Market

Based on the type of product, the market is segmented into HPAPI and highly potent finished dosage forms. At present, HPAPI segment holds the maximum share of the cytotoxic drugs & HPAPI manufacturing market. This trend is unlikely to change in the near future.

Very Large Players are Likely to Dominate the Cytotoxic Drugs & HPAPI Manufacturing Market During the Forecast Period

Based on the company size, the market is segmented into small, mid-sized, large and very large companies. At present, very large companies hold the maximum share of the cytotoxic drugs & HPAPI manufacturing market. This trend is likely to remain the same in the coming decade.

By Scale of Operation, Commercial Scale is Likely to Dominate the Cytotoxic Drugs and HPAPI Manufacturing Market

Based on scales of operation, the market is segmented into preclinical, clinical and commercial scales. It is worth highlighting that, at present, commercial scale holds a larger share of the cytotoxic drugs and HPAPI manufacturing market. This trend is likely to remain the same in the forthcoming years.

Biologics is the Fastest Growing Segment of the Cytotoxic Drugs and HPAPI Manufacturing Market During the Forecast Period

Based on the type of molecule, the market is segmented into small molecules and biologics. It is worth highlighting that, at present, small molecules dominate the cytotoxic drugs and HPAPI manufacturing market. This is primarily due to the fact the CMOs have invested and expanded their capabilities for highly potent small molecules. It is important to note the demand for highly potent drugs is on the rise, therefore the market for biologics is expected to grow at a faster pace in the coming decade.

Oral FDFs are Likely to Dominate the Cytotoxic Drugs and HPAPI Manufacturing Market During the Forecast Period

Based on the type of highly potent finished dosage forms, the market is segmented into injectables, oral solids, creams and other FDFs. It is worth highlighting that, at present, oral FDFs capture the highest share of the cytotoxic drugs and HPAPI manufacturing market. This trend is likely to remain the same in the coming decade owing to the benefits offered by oral formulations, such as cost-efficiency for manufacturers, comfort and ease of use for patients.

Europe Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the world. The majority of the share is expected to be captured by players based in Europe. This is due to the fact that there are well-established players in this region with considerable installed capacities and capabilities. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Cytotoxic Drugs & HPAPI Manufacturing Market

• AbbVie
• Cambrex
• Catalent
• Pfizer CentreOne
• Piramal Pharma Solutions
• Abzena
• Aenova
• CARBOGEN AMCIS
• Hovione
• Lonza
• Intas Pharmaceuticals
• Scinopharm
• STA Pharmaceutical (a WuXi AppTec company)
• Syngene
• Teva API

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Owner and Director, Company A
• Vice President and Chief Operating Officer and Business Director, Company B
• ILC Dover, Vice President, Company C
• Ex-Group Product Manager and Ex-Director-Business Development, Company D
• Business Development Director, Company E
• Managing Director, Company F
• Ex-Business Head, Formulations and Finished Products, Company G
• Ex-Site Head, Company H
• Ex-Senior Manager, Business Development, Company I
• Marketing and Sales Manager, Pharma, Company J
• Ex-Business Development Technician, Company K

Cytotoxic Drugs and HPAPI Manufacturing Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cytotoxic drugs and HPAPI manufacturing market, focusing on key market segments, including [A] type of product, [B] company size, [C] scale of operation, [D] type of molecule, [E] type of highly potent finished dosage form and [F] key geographical regions.
• Market Landscape: A comprehensive evaluation of companies involved in the contract manufacturing of HPAPI and cytotoxic drugs, considering various parameters, such as [A] year of establishment, [B] company size (in terms of number of employees), [C] location of headquarters, [D] location of manufacturing facility, [E] area of manufacturing facility, [F] scale of operation, [G] type of product manufactured, [H] type of highly potent finished dosage form, [G] Occupational Exposure Limit, [H] type of molecule manufactured, [H] type of primary packaging system, [I] regulatory certifications / accreditations received and [J] type of service(s) offered.
• Company Competitiveness Analysis: A comprehensive competitive analysis of HPAPI and cytotoxic drug contract manufacturers, examining factors, such as [A] supplier strength and [B] service strength.
• Company Profiles: In-depth profiles of key industry players offering contract manufacturing services for HPAPI and cytotoxic drugs, focusing on [A] company overviews, [B] HPAPI and cytotoxic drug-related service portfolio, [C] dedicated facilities, [D] recent developments and [E] an informed future outlook.
• Partnerships and Collaborations: An analysis of partnerships established in this sector based on relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] scale of operation, [D] type of product, [E] most active players (in terms of number of deals inked) and [F] regional distribution of partnership activity that have been undertaken in cytotoxic drugs and HPAPI manufacturing market.
• Recent Expansions: An examination of the different expansion efforts made by the HPAPI and cytotoxic drug contract manufacturers in this field to enhance their manufacturing capabilities. This analysis considers various factors, including the [A] year of expansion, [B] type of expansion, [C] company size, [D] location of headquarters, [E] scale of operation, [F] type of product, [G] location of expanded facility, [H] area of expanded facility, [I] amount invested in expansions, [J] most active players (in terms of number of recent expansions) and [K] geographical distribution.
• Capacity Analysis: Estimation of global HPAPI manufacturing capacity, derived from data provided by various stakeholders in the public domain. This analysis emphasizes the distribution of the available capacity on the basis of [A] company size (small, mid-sized and large), [B] scale of operation (preclinical, clinical and commercial) and [C] key geographical regions (North America, Europe and Asia-Pacific).
• Regional Capability Assessment Analysis: A regional capability assessment framework that compares the HPAPI and cytotoxic drug manufacturing capabilities across key geographies, based on several parameters, such as [A] the number of HPAPI and cytotoxic drug contract manufacturers, [B] number of HPAPI and cytotoxic drug manufacturing facilities, [C] number of facility expansions and [D] installed HPAPI capacity in that particular geographical region.
• SWOT Analysis: A SWOT analysis, focusing on key drivers and challenges that are likely to impact the industry's evolution.
• Case Study: A case study on companies offering manufacturing services for antibody drug conjugate (ADCs). The chapter also highlights the key components of ADCs and the key challenges associated with the manufacturing of these products. Further, the chapter presents a list of players that provide contract manufacturing services for ADCs.

Key Questions Answered in this Report

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What are the factors that are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 15% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Key Market Insights
• 1.3. Scope of the Report
• 1.4. Research Methodology
• 1.5. Frequently Asked Questions
• 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

• 3.1. Chapter Overview
• 3.2. High Potency Active Pharmaceutical Ingredients
  • 3.2.1. Classification by Potency
    • 3.2.1.1. Classification of HPAPIs
  • 3.2.2. Different Types of HPAPIs
    • 3.2.2.1. Antibody Drug Conjugates
    • 3.2.2.2. Cytotoxic Drugs
    • 3.2.2.3. Peptides
    • 3.2.2.4. Hormones
    • 3.2.2.5. Beta-Lactam Compounds
    • 3.2.2.6. Prostaglandins
    • 3.2.2.7. Cytostatics
    • 3.2.2.8. Steroids
  • 3.2.3. Considerations for Handling HPAPIs
  • 3.2.4. Contract Manufacturing of HPAPIs and Cytotoxic Drugs
    • 3.2.4.1. Key Considerations While Selecting a Contract Manufacturing Partner
  • 3.2.5. Regulatory Considerations for Manufacturing HPAPIs
  • 3.2.6. Concluding Remarks

4. MARKET LANDSCAPE

• 4.1. Chapter Overview
• 4.2. HPAPI and Cytotoxic Drug Contract Manufacturers: Overall Market Landscape
  • 4.2.1. Analysis by Year of Establishment
  • 4.2.2. Analysis by Company Size
  • 4.2.3. Analysis by Location of Headquarters
  • 4.2.4. Analysis by Company Size and Location of Headquarters
  • 4.2.5. Analysis by Location of Manufacturing Facility
  • 4.2.6. Analysis by Area of Manufacturing Facility
  • 4.2.7. Analysis by Scale of Operation
  • 4.2.8. Analysis by Type of Product Manufactured
  • 4.2.9. Analysis by Location of Manufacturing Facility and Type of Product Manufactured
  • 4.2.10. Analysis by Type of Finished Dosage Form
  • 4.2.11. Analysis by Occupational Exposure Limit (OEL)
  • 4.2.12. Analysis by Type of Molecule Manufactured
  • 4.2.13. Analysis by Type of Primary Packaging System
  • 4.2.14. Analysis by Regulatory Certification / Accreditation Received
  • 4.2.15. Analysis by Type of Service(s) Offered

5. COMPANY COMPETITIVENESS ANALYSIS

• 5.1. Chapter Overview
• 5.2. Assumptions and Key Parameters
• 5.3. Methodology
• 5.4. HPAPI Contract Manufacturers: Company Competitiveness Analysis
  • 5.4.1. HPAPI Contract Manufacturers based in North America
  • 5.4.2. HPAPI Contract Manufacturers based in Europe
  • 5.4.3. HPAPI Contract Manufacturers based in Asia-Pacific and Rest of the World
• 5.5. Highly Potent FDF Contract Manufacturers: Company Competitiveness Analysis
  • 5.5.1. Highly Potent FDF Contract Manufacturers based in North America
  • 5.5.2. Highly Potent FDF Contract Manufacturers based in Europe
  • 5.5.3. Highly Potent FDF Contract Manufacturers based in Asia-Pacific and Rest of the World
• 5.6. HPAPI and Highly Potent FDF Contract Manufacturers: Company Competitiveness Analysis
  • 5.6.1. HPAPI and Highly Potent FDF Contract Manufacturers based in North America
  • 5.6.2. HPAPI and Highly Potent FDF Contract Manufacturers based in Europe
  • 5.6.3. HPAPI and Highly Potent FDF Contract Manufacturers based in Asia-Pacific and Rest of the World

6. COMPANY PROFILES: HPAPI AND CYTOTOXIC DRUG MANUFACTURERS IN NORTH AMERICA

• 6.1. Chapter Overview
• 6.2. AbbVie
  • 6.2.1. Company Overview
  • 6.2.2. HPAPI and Cytotoxic Drug Manufacturing Focused Service Offerings
  • 6.2.3. Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities
  • 6.2.4. Recent Developments and Future Outlook
• 6.3. Cambrex
  • 6.3.1. Company Overview
  • 6.3.2. HPAPI and Cytotoxic Drug Manufacturing Focused Service Offerings
  • 6.3.3. Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities
  • 6.3.4. Recent Developments and Future Outlook
• 6.4. Catalent
  • 6.4.1. Company Overview
  • 6.4.2. HPAPI and Cytotoxic Drug Manufacturing Focused Service Offerings
  • 6.4.3. Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities
  • 6.4.4. Recent Developments and Future Outlook
• 6.5. Pfizer CentreOne
  • 6.5.1. Company Overview
  • 6.5.2. HPAPI and Cytotoxic Drug Manufacturing Focused Service Offerings
  • 6.5.3. Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities
  • 6.5.4. Recent Developments and Future Outlook
• 6.6. Piramal Pharma Solutions
  • 6.6.1. Company Overview
  • 6.6.2. HPAPI and Cytotoxic Drugs Manufacturing Focused Service Offerings
  • 6.6.3. Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities
  • 6.6.4. Recent Developments and Future Outlook

7. COMPANY PROFILES: HPAPI AND CYTOTOXIC DRUG MANUFACTURERS IN EUROPE

• 7.1. Chapter Overview
• 7.2. Abzena
  • 7.2.1. Company Overview
  • 7.2.2. HPAPI and Cytotoxic Drug Manufacturing Focused Service Offerings
  • 7.2.3. Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities
  • 7.2.4. Recent Developments and Future Outlook
• 7.3. Aenova
  • 7.3.1. Company Overview
  • 7.3.2. HPAPI and Cytotoxic Drug Manufacturing Focused Service Offerings
  • 7.3.3. Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities
  • 7.3.4. Recent Developments and Future Outlook
• 7.4. CARBOGEN AMCIS
  • 7.4.1. Company Overview
  • 7.4.2. HPAPI and Cytotoxic Drug Manufacturing Focused Service Offerings
  • 7.4.3. Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities
  • 7.4.4. Recent Developments and Future Outlook
• 7.5. Hovione
  • 7.5.1. Company Overview
  • 7.5.2. HPAPI and Cytotoxic Drug Manufacturing Focused Service Offerings
  • 7.5.3. Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities
  • 7.5.4. Recent Developments and Future Outlook
• 7.6. Lonza
  • 7.6.1. Company Overview
  • 7.6.2. HPAPI and Cytotoxic Drugs Manufacturing Focused Service Offerings
  • 7.6.3. Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities
  • 7.6.4. Recent Developments and Future Outlook

8. COMPANY PROFILES: HPAPI AND CYTOTOXIC DRUG MANUFACTURERS IN ASIA-PACIFIC AND REST OF

THE WORLD

• 8.1. Chapter Overview
• 8.2. Intas Pharmaceuticals
  • 8.2.1. Company Overview
  • 8.2.2. HPAPI and Cytotoxic Drug Manufacturing Focused Service Offerings
  • 8.2.3. Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities
  • 8.2.4. Recent Developments and Future Outlook
• 8.3. Scinopharm
  • 8.3.1. Company Overview
  • 8.3.2. HPAPI and Cytotoxic Drugs Manufacturing Focused Service Offerings
  • 8.3.3. Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities
  • 8.3.4. Recent Developments and Future Outlook
• 8.4. STA Pharmaceutical (a WuXi AppTec company)
  • 8.4.1. Company Overview
  • 8.4.2. HPAPI and Cytotoxic Drug Manufacturing Focused Service Offerings
  • 8.4.3. Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities
  • 8.4.4. Recent Developments and Future Outlook
• 8.5. Syngene
  • 8.5.1. Company Overview
  • 8.5.2. HPAPI and Cytotoxic Drug Manufacturing Focused Service Offerings
  • 8.5.3. Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities
  • 8.5.4. Recent Developments and Future Outlook
• 8.6. Teva API
  • 8.6.1. Company Overview
  • 8.6.2. HPAPI and Cytotoxic Drug Manufacturing Focused Service Offerings
  • 8.6.3. Dedicated HPAPI and Cytotoxic Drug Manufacturing Facilities
  • 8.6.4. Recent Developments and Future Outlook

9. PARTNERSHIPS AND COLLABORATIONS

• 9.1. Chapter Overview
• 9.2. Partnership Models
• 9.3. HPAPI and Cytotoxic Drugs: List of Partnerships and Collaborations
  • 9.3.1. Analysis by Year of Partnership
  • 9.3.2. Analysis by Type of Partnership
  • 9.3.3. Analysis by Year and Type of Partnership
  • 9.3.4. Analysis by Scale of Operation
  • 9.3.5. Analysis by Type of Product
  • 9.3.6. Analysis by Type of Partnership and Type of Product
  • 9.3.7. Analysis of Amount Invested Via Acquisitions
  • 9.3.8. Analysis by Type of Partner
  • 9.3.9. Most Active Players: Analysis by Number of Partnerships
  • 9.3.10. Analysis by Geography
    • 9.3.10.1. Intracontinental and Intercontinental Deals
    • 9.3.10.2. International and Local Deals

10. RECENT EXPANSIONS

• 10.1. Chapter Overview
• 10.2. HPAPI and Cytotoxic Drugs: List of Recent Expansions
  • 10.2.1. Analysis by Year of Expansion
  • 10.2.2. Analysis by Type of Expansion
  • 10.2.3. Analysis by Year and Type of Expansion
  • 10.2.4. Analysis by Company Size and Location of Headquarters
  • 10.2.5. Analysis by Scale of Operation
  • 10.2.6. Analysis by Type of Expansion and Scale of Operation
  • 10.2.7. Analysis by Type of Product
  • 10.2.8. Analysis by Type of Expansion and Type of Product
  • 10.2.9. Analysis by Location of Expanded Facility
  • 10.2.10. Analysis by Type of Expansion and Location of Expanded Facility
  • 10.2.11. Analysis by Expanded Facility Area
  • 10.2.12. Analysis by Amount Invested on Expansions
  • 10.2.13. Most Active Players: Analysis by Number of Recent Expansions
  • 10.2.14. Geographical Analysis
    • 10.2.14.1. Analysis by Continent
    • 10.2.14.2. Analysis by Country

11. CAPACITY ANALYSIS

• 11.1. Chapter Overview
• 11.2. Key Assumptions and Methodology
• 11.3. HPAPI Contract Manufacturers: Global Installed Capacity
  • 11.3.1. Analysis by Range of Installed Capacity
  • 11.3.2. Analysis by Company Size
  • 11.3.3. Analysis by Scale of Operation
  • 11.3.4. Analysis by Location of Manufacturing Facility
    • 11.3.4.1. Analysis of HPAPI Contract Manufacturing Capacity Installed in North America
    • 11.3.4.2. Analysis of HPAPI Contract Manufacturing Capacity Installed in Europe
    • 11.3.4.3. Analysis of HPAPI Contract Manufacturing Capacity Installed in Asia-Pacific and Rest of the World
  • 11.3.5. Concluding Remarks

12. REGIONAL CAPABILITY ASSESSMENT ANALYSIS

• 12.1. Chapter Overview
• 12.2. Assumptions and Key Parameters
• 12.3. HPAPI and Cytotoxic Drug Manufacturing Capabilities in North America
• 12.4. HPAPI and Cytotoxic Drug Manufacturing Capabilities in Europe
• 12.5. HPAPI and Cytotoxic Drug Manufacturing Capabilities in Asia-Pacific
• 12.6. HPAPI and Cytotoxic Drug Manufacturing Capabilities in Rest of the World
• 12.7. Concluding Remarks

13. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

• 13.1. Chapter Overview
• 13.2. Assumptions and Key Parameters
  • 12.2.1. Scenario 1
  • 12.2.1. Scenario 2
  • 12.2.1. Scenario 3
  • 12.2.1. Scenario 4
• 13.3. Concluding Remarks

14. MARKET SIZING AND OPPORTUNITY ANALYSIS

• 14.1. Chapter Overview
• 14.2. Forecast Methodology and Key Assumptions
• 14.3. Global HPAPI and Cytotoxic Drug Contract Manufacturing Market, till 2035
  • 14.3.1. HPAPI and Cytotoxic Drug Contract Manufacturing Market: Analysis by Type of Product, till 2035
  • 14.3.2. HPAPI and Cytotoxic Drugs Contract Manufacturing Market: Analysis by Company Size, till 2035
  • 14.3.3. HPAPI and Cytotoxic Drugs Contract Manufacturing Market: Analysis by Scale of Operation, till 2035
  • 14.3.4. HPAPI and Cytotoxic Drugs Contract Manufacturing Market: Analysis by Type of Molecule, till 2035
  • 14.3.5. HPAPI and Cytotoxic Drugs Contract Manufacturing Market: Analysis by Type of Highly Potent Finished Dosage Forms, till 2035
  • 14.3.6 HPAPI and Cytotoxic Drugs Contract Manufacturing Market: Analysis by Geography, till 2035
  • 14.3.7. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in North America, till 2035
    • 14.3.7.1. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in the US, till 2035
    • 14.3.7.2. HPAPI and Cytotoxic Drug Contract Manufacturing Market in Canada, till 2035
    • 14.3.7.3. HPAPI and Cytotoxic Drug Contract Manufacturing Market in Mexico, till 2035
  • 14.3.8. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Europe, till 2035
    • 14.3.8.1. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in the UK, till 2035
    • 14.3.8.2. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Italy, till 2035
    • 14.3.8.3. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Germany, till 2035
    • 14.3.8.4. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in France, till 2035
    • 14.3.8.5. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Spain, till 2035
    • 14.3.8.6. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Rest of Europe, till 2035
  • 14.3.9. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Asia-Pacific, till 2035
    • 14.3.9.1. HPAPI and Cytotoxic Drug Contract Manufacturing Market in China, till 2035
    • 14.3.9.2. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in India, till 2035
    • 14.3.9.3. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in Rest of Asia-Pacific, till 2035
  • 14.3.10. HPAPI and Cytotoxic Drugs Contract Manufacturing Market in the Rest of the World, till 2035

15. SWOT ANALYSIS

• 15.1. Chapter Overview
• 15.2. Strengths
• 15.3. Weaknesses
• 15.4. Opportunities
• 15.5. Threats
• 15.6. Concluding Remarks

16. CASE-IN-POINT: CONTRACT MANUFACTURING OF ANTIBODY DRUG CONJUGATES

• 16.1. Chapter Overview
• 16.2. Key Components of Antibody Drug Conjugates
  • 16.2.1. Antibody
  • 16.2.2. Cytotoxin
  • 16.2.3. Linker
• 16.3. Overview of ADC Manufacturing
  • 16.3.1. Key Process Steps
  • 16.3.2. Challenges Associated with ADC Manufacturing
  • 16.3.3. Growing Trend of Outsourcing in ADC Manufacturing
• 16.4. Challenges Associated with Supply Chain and Method Transfer
  • 16.4.1. Growing Demand for One-Stop-Shops and Integrated Service Providers
• 16.5. Key Considerations for Selecting a CMO Partner
• 16.6. ADC Contract Manufacturing Service Providers: Overall Market Landscape
  • 16.6.1. Analysis by Year of Establishment
  • 16.6.2. Analysis by Company Size
  • 16.6.3. Analysis by Location of Headquarters
  • 16.6.4. Analysis by Service(s) Offered
• 16.7. Concluding Remarks

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS

• 18.1. Chapter Overview
• 18.2. Company A
  • 18.2.1. Company Snapshot
  • 18.2.2. Interview Transcript: Vice President and Chief Operating Officer and Business Director
• 18.3. Company B
  • 18.3.1. Company Snapshot
  • 18.3.2. Interview Transcript: Ex-Group Product Manager and Ex-Director-Business Development
  • 18.3.3. Interview Transcript: Business Development Associate
• 18.4. Company C
  • 18.4.1. Company Snapshot
  • 18.4.2. Interview Transcript: Business Development Director
• 18.5. Company D
  • 18.5.1. Company Snapshot
  • 18.5.2. Interview Transcript: Managing Director
• 18.6. Company E
  • 18.6.1. Company Snapshot
  • 18.6.2. Interview Transcript: Ex-Business Head, Formulations and Finished Products
• 18.7. Company F
  • 18.7.1. Company Snapshot
  • 18.7.2. Interview Transcript: Ex-Site Head, Grangemouth
• 18.8. Company G
  • 18.8.1. Company Snapshot
  • 18.8.2. Interview Transcript: Ex-Senior Manager, Business Development
• 18.9. Company H
  • 18.9.1. Company Snapshot
  • 18.9.2. Interview Transcript: Marketing and Sales Manager, Pharma
• 18.10. Company I
  • 18.10.1. Company Snapshot
  • 18.10.2. Interview Transcript: Ex-Business Development Technician

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS